Alamar Biosciences, Inc. Launches NULISAseq Neuro 220 Panel To Enable Ultra-Sensitive Measurement of 220 Neurological Biomarkers

Alamar Biosciences, Inc., a company known for its leadership in precision proteomics and its commitment to improving early disease detection, has announced the launch of the NULISAseq Neuro 220 Panel. This new panel allows researchers to measure 220 biomarkers from a single sample using multiplexed technology, while still maintaining extremely high sensitivity and strong specificity. 

It builds upon the company’s earlier NULISAseq CNS Disease Panel 120 and includes additional biomarker content developed with support from The Michael J. Fox Foundation for Parkinson’s Research. The updated panel also features an expanded portfolio of highly selective Tau protein assays, covering both brain-derived and peripheral isoforms of total tau along with several phosphorylated forms, including pTau217, pTau181, pTau205, pTau212, and pTau231. 

Alamar notes that this represents one of the most comprehensive collections of Tau assays available within a single panel and demonstrates the capability of NULISA chemistry to distinguish between organ-specific isoforms and a wide variety of post-translational modifications. Representatives from The Michael J. Fox Foundation expressed strong support for the advancement of these assays. Nicole Polinski, PhD, Director of Research Programs at the foundation, shared that such tools are essential for deepening scientific understanding of Parkinson’s disease progression and could accelerate efforts to develop reliable diagnostic and prognostic markers.

Alamar’s founder, chairman, and chief executive officer, Dr. Yuling Luo, explained that this launch marks another important step in the company’s mission to innovate in the field of precision proteomics. By expanding their panel to capture a broader range of neurodegenerative disease biology, Alamar aims to better support research into complex conditions such as Alzheimer’s and Parkinson’s. Dr. Luo also acknowledged the valuable partnership with The Michael J. Fox Foundation in helping to advance novel biomarker content for the scientific community.

The NULISAseq Neuro 220 Panel has been designed to support a wide range of neurodegenerative disease research areas. It is applicable to conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, frontotemporal dementia, Lewy body dementia, progressive supranuclear palsy, amyotrophic lateral sclerosis, Huntington’s disease, vascular dementia, gliomas, and traumatic brain injury. 

The panel’s high sensitivity and specificity also make it suitable for use with non-invasive sample collection methods and for early or pre-symptomatic detection. Its compatibility with automated workflows through the ARGO HT System provides consistent results, simplifies laboratory operations, and enables researchers to better study disease diversity, identify co-existing pathologies, and detect markers that may predict disease progression or treatment response.

Alamar will showcase the new panel at AD/PD 2026, scheduled from March 17–21 in Copenhagen, Denmark. During the event, Dr. Henrik Zetterberg will present data highlighting how the NULISAseq Neuro 220 Panel can improve research on neurodegenerative diseases during Alamar’s product theater session on March 18. Dr. Zetterberg emphasized that being able to measure a broad set of neurodegenerative biomarkers in a single, highly sensitive assay represents a meaningful advancement for both translational and clinical research. 

According to him, innovations like the NULISAseq Neuro 220 Panel help scientists gain deeper insights into disease mechanisms and support the development of more accurate diagnostics and effective therapies. Additional findings showcasing the power of the NULISA platform for ultra-sensitive, multiplexed detection of key neurological biomarkers will be presented at AD/PD 2026, including more than 11 oral presentations and 25 scientific posters.